CN112469402B - 可口服给药且缓释的药物剂型 - Google Patents

可口服给药且缓释的药物剂型 Download PDF

Info

Publication number
CN112469402B
CN112469402B CN201980049223.8A CN201980049223A CN112469402B CN 112469402 B CN112469402 B CN 112469402B CN 201980049223 A CN201980049223 A CN 201980049223A CN 112469402 B CN112469402 B CN 112469402B
Authority
CN
China
Prior art keywords
formula
compound
shell
core
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201980049223.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112469402A (zh
Inventor
A·斯特罗耶
C·洛拜克
P·谢尔诺
K·洛维斯
P·鲁本鲍尔
H·席尔默
D·格罗斯巴赫
T·雅各布
B·奥利尼克
J·库塞尔
D·比勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Pharma AG
Original Assignee
Bayer AG
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/043,567 external-priority patent/US10905667B2/en
Application filed by Bayer AG, Bayer Pharma AG filed Critical Bayer AG
Publication of CN112469402A publication Critical patent/CN112469402A/zh
Application granted granted Critical
Publication of CN112469402B publication Critical patent/CN112469402B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980049223.8A 2018-07-24 2019-07-19 可口服给药且缓释的药物剂型 Expired - Fee Related CN112469402B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18185127.0 2018-07-24
US16/043,567 US10905667B2 (en) 2018-07-24 2018-07-24 Orally administrable modified-release pharmaceutical dosage form
US16/043,567 2018-07-24
EP18185127 2018-07-24
PCT/EP2019/069561 WO2020020789A1 (de) 2018-07-24 2019-07-19 Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung

Publications (2)

Publication Number Publication Date
CN112469402A CN112469402A (zh) 2021-03-09
CN112469402B true CN112469402B (zh) 2024-05-14

Family

ID=67314781

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980049223.8A Expired - Fee Related CN112469402B (zh) 2018-07-24 2019-07-19 可口服给药且缓释的药物剂型

Country Status (22)

Country Link
EP (1) EP3826627B1 (cg-RX-API-DMAC7.html)
JP (1) JP2021532113A (cg-RX-API-DMAC7.html)
KR (1) KR20210035235A (cg-RX-API-DMAC7.html)
CN (1) CN112469402B (cg-RX-API-DMAC7.html)
AU (1) AU2019311234A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020026644A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107169A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000160A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000450A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210043A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000015A (cg-RX-API-DMAC7.html)
EC (1) ECSP21003707A (cg-RX-API-DMAC7.html)
IL (1) IL280083A (cg-RX-API-DMAC7.html)
JO (1) JOP20210019A1 (cg-RX-API-DMAC7.html)
MA (1) MA53368A (cg-RX-API-DMAC7.html)
MX (1) MX2021000904A (cg-RX-API-DMAC7.html)
PE (1) PE20210415A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550170A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100369WA (cg-RX-API-DMAC7.html)
TW (1) TW202019402A (cg-RX-API-DMAC7.html)
UY (1) UY38308A (cg-RX-API-DMAC7.html)
WO (1) WO2020020789A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202112359A (zh) 2019-06-07 2021-04-01 德商拜耳廠股份有限公司 sGC活化劑於治療眼科疾病之用途
CN112557533A (zh) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 一种恩格列净的分析方法
EP4339184B1 (en) * 2021-05-14 2026-08-12 Medshine Discovery Inc. Alkyl carboxylic acid compounds and application thereof
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂
CN117982443B (zh) * 2022-10-31 2026-03-06 优辉药业(北京)有限公司 一种达格列净二甲双胍缓释片剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
CN103796989A (zh) * 2011-04-13 2014-05-14 拜耳知识产权有限责任公司 支化的3-苯基丙酸衍生物和其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
DE3868077D1 (de) 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
PE20211391A1 (es) 2017-12-01 2021-07-27 Bayer Pharma AG Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
CN103796989A (zh) * 2011-04-13 2014-05-14 拜耳知识产权有限责任公司 支化的3-苯基丙酸衍生物和其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
An Insight to Osmotic Drug Delivery;Rashmi Sareen等;Current Drug Delivery;第9卷(第3期);第285-296页 *
韦超等编.《药剂学 第2版》.河南科学技术出版社,2012,(第2版),第354-355页. *

Also Published As

Publication number Publication date
WO2020020789A1 (de) 2020-01-30
SG11202100369WA (en) 2021-02-25
EP3826627B1 (de) 2023-10-18
PE20210415A1 (es) 2021-03-04
CO2021000450A2 (es) 2021-01-29
PH12021550170A1 (en) 2021-09-13
TW202019402A (zh) 2020-06-01
JOP20210019A1 (ar) 2021-01-24
MA53368A (fr) 2021-06-02
MX2021000904A (es) 2021-03-31
KR20210035235A (ko) 2021-03-31
IL280083A (en) 2021-03-01
CL2021000160A1 (es) 2021-06-04
UY38308A (es) 2020-02-28
ECSP21003707A (es) 2021-02-26
CA3107169A1 (en) 2020-01-30
EP3826627A1 (de) 2021-06-02
CR20210043A (es) 2021-03-09
BR112020026644A2 (pt) 2021-03-23
CN112469402A (zh) 2021-03-09
AU2019311234A1 (en) 2021-02-04
JP2021532113A (ja) 2021-11-25
DOP2021000015A (es) 2021-02-15
EP3826627C0 (de) 2023-10-18

Similar Documents

Publication Publication Date Title
US20220257547A1 (en) Orally administrable modified-release pharmaceutical dosage form
DK2370065T3 (en) Pharmaceutical drug form containing nifedipine or nisoldipine AND A angiotensin II antagonist and / or a diuretic
CN112469402A (zh) 可口服给药且缓释的药物剂型
JP2017008081A (ja) 血圧上昇および糖尿病性腎症を処置するための、ビフェニルスルホンアミドエンドセリンおよびアンジオテンシンii受容体アンタゴニストの経口製剤
US20200237648A1 (en) Orally administrable modified-released pharmaceutical dosage form
ZA200703866B (en) Pharmaceutical formulation containing a release rate controlling compositions
WO2003082805A1 (en) Low water-soluble venlafaxine salts
KR20150027284A (ko) 5-클로로-n-({(5s)-2-옥소-3-[4-(3-옥소-4-모르폴리닐)페닐]-1,3-옥사졸리딘-5-일}메틸)-2-티오펜카르복스아미드를 포함하는 제약 투여 형태
US20210283046A1 (en) Pharmaceutical dosage form which can be administered orally and has modified release
US10588892B2 (en) Pharmaceutical composition comprising sacubitril and valsartan
WO2022112213A1 (en) Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
HK40041248A (en) Pharmaceutical dosage form which can be administered orally and has modified release
HK40041640A (en) Pharmaceutical dosage form which can be administered orally and has modified release
EA042489B1 (ru) Фармацевтическая композиция, включающая сакубитрил и валсартан
HK40060377B (en) Pharmaceutical combination preparation comprising ezetimibe and losartan
CN110452156A (zh) 多奈哌齐与厄贝沙坦共晶物及制备方法和其组合物与用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041248

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240514

CF01 Termination of patent right due to non-payment of annual fee